本文へ移動
cccskills
無料GitHub で公開

endo-assess-cgm-factors-influencing-success

Evaluates patient-specific factors such as lifestyle, motivation, and barriers that may affect successful CGM use. Triggered when clinicians discuss patient’s readiness for CGM or identify obstacles to consistent sensor wear.

dromlakhani/MD2SKILL
インストール方法を見る

含まれるファイル（1）

  • SKILL.md2.5 KB

SKILL.md（原文）

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Assess factors influencing success with CGM

STEP 1 — Gather Information

Collect patient understanding that CGM does not replace SMBG, self-care behaviors influencing success, knowledge of CGM components (receiver, sensor, transmitter), comprehension of how CGM data differ from SMBG, ability to use trend data for insulin adjustments, SMBG calibration practices, sensor site selection and care skills, alarm settings preferences, and psychosocial factors (motivation, lifestyle, barriers).

STEP 2 — Rule In / Rule Out

Determine if the patient understands CGM is adjunctive to SMBG and is willing to perform required SMBG calibrations; if not, rule out CGM initiation until education addresses this gap.

STEP 3 — Classify or Stratify

Classify readiness: (A) Ready – understands adjunctive role, willing to calibrate, has adequate dexterity/site care ability, motivated; (B) Conditional – deficits in knowledge or site care but correctable with training; (C) Not suitable – unwilling/unable to perform SMBG, severe cognitive/physical impairment preventing use, or lack of insurance/access.

STEP 4 — Decide

If Ready: proceed with CGM prescription and initial training. If Conditional: schedule targeted education sessions addressing specific gaps before initiation. If Not suitable: defer CGM and explore alternative glucose monitoring strategies.

Clinical Guardrails / Mimics / Pitfalls

Do not assume CGM eliminates need for SMBG; avoid overlooking alarm fatigue by not customizing alerts; neglect sensor rotation leading to skin irritation; fail to assess financial/insurance coverage for sensors; ignore psychosocial barriers like depression or low motivation that impair adherence.

Concrete Clinical Example

A 34‑year‑old with T1DM, A1C 8.6%, expresses interest in CGM, understands it complements fingersticks, agrees to twice‑daily calibrations, has good dexterity, no cognitive impairment, and insurance covers sensors → classified as Ready; CGM prescribed and training scheduled.

Source: Diabetes Technology—Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2534

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

ログインしてレビューを書く

同じリポジトリのスキル

概要と使いどころ

780g-pump-adjustment

無料

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-acth-stim-test-interpretation

無料

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-adrenal-crisis-treatment

無料

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-ai-education

無料

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-lt4-monitoring

無料

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-cortisol-cutoff-ai-diagnosis

無料

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する